Can Cannabis Help With Depression? Exploring the Endocannabinoid System and Mood Regulation

Depression is one of the most prevalent mental health conditions in the world, affecting an estimated 280 million people globally, according to the World Health Organization. Yet for many patients, conventional antidepressants either fail to provide adequate relief or carry side effects significant enough to discourage long-term use.

As the trend towards the legalization of cannabis becomes more widespread throughout the US, there is an increasing number of individuals who are wondering if cannabinoids can serve as another treatment option in helping individuals cope with their depression. There is quite a bit of information available on this topic.

Understanding Depression Beyond Serotonin

Depression is not simply thought to be about a deficit of serotonin anymore. What neuroscience has discovered at present is that depression is a multifactorial illness involving dysregulation within several neurochemical pathways, including the endocannabinoid pathway, the hypothalamic-pituitary-adrenal (HPA) axis, and inflammatory pathways.

For decades, the dominant explanation for depression centered on low serotonin levels, which formed the rationale for selective serotonin reuptake inhibitors (SSRIs) as the standard first-line treatment. While SSRIs remain widely prescribed and effective for many patients, a landmark 2022 umbrella review published in Molecular Psychiatry by Moncrieff and colleagues found no consistent evidence that people with depression have lower serotonin levels than those without it, challenging the chemical imbalance narrative that has guided treatment for thirty years.

This does not imply that SSRIs do not work. Rather, it means that there is more to the mechanism than initially thought. Some of the other aspects of depression include:

• Chronic neuroinflammation driven by elevated cytokines and microglial activation
• Neuroplasticity disorders and decreased neurogenesis in the hippocampus
• Malfunction of the HPA axis resulting in high cortisol levels and increased stress sensitivity
• Deficiency of the endocannabinoid system is responsible for emotional regulation and stress
• Disrupted sleep architecture, which compounds mood instability over time

Understanding depression as a multisystem condition opens the door to exploring how cannabinoids, which interact with several of these systems simultaneously, might play a role in symptom management.

What Is the Endocannabinoid System?

The endocannabinoid system (ECS) is a cell-signaling network present throughout the brain and body that plays a central role in regulating mood, stress response, sleep, appetite, and emotional memory. It operates through two primary receptor types, CB1 and CB2, and two internally produced cannabinoid molecules, anandamide and 2-AG.

The National Institute on Drug Abuse states that the ECS is one of the most prevalent receptor systems within the human brain, with CB1 receptors being abundant within areas involved in the regulation of emotions like the prefrontal cortex, amygdala, hippocampus, and anterior cingulate cortex. These are the areas responsible for the regulation of depression, anxiety, and stress.

Anandamide, often called the “bliss molecule,” is an endogenous cannabinoid that binds to CB1 receptors and produces effects associated with mood elevation, stress buffering, and emotional resilience. When anandamide signaling is robust, the brain is better equipped to modulate fear responses, recover from stress, and maintain emotional equilibrium. When it is depleted or disrupted, the result closely mirrors clinical depression.

Cannabis exerts its effects through the introduction of cannabinoids from the plant, which include THC and CBD, which act on the same receptors in a manner similar to the body’s endocannabinoids.

How Cannabis Interacts With Mood Regulation

THC and CBD interact with the endocannabinoid system through distinct mechanisms, producing meaningfully different effects on mood. THC binds directly to CB1 receptors and produces psychoactive effects, including euphoria, altered perception, and, in some cases, anxiety. CBD does not bind directly to CB1 receptors but modulates the ECS indirectly, including by inhibiting the breakdown of anandamide, effectively increasing its availability in the brain.

The effect of marijuana on mood happens via several mechanisms:

• THC activates the neurotransmitter dopamine through the mesolimbic pathway, resulting in pleasure and reward sensations that can provide short-term relief from depression
• CBD increases anandamide availability by inhibiting fatty acid amide hydrolase (FAAH), the enzyme responsible for breaking it down
• Both cannabinoids have demonstrated anti-inflammatory properties in preclinical studies, which may address the neuroinflammatory component of depression.
• THC and CBD both modulate the HPA axis stress response, with CBD in particular showing cortisol-reducing effects in several human studies
• Cannabinoids have shown preliminary evidence of neurogenic effects in animal models, meaning they may support the growth of new neurons in the hippocampus, a process disrupted in chronic depression.

According to a 2014 review published in Neuroscience and Biobehavioral Reviews by Ménard and colleagues, the ECS plays a critical modulatory role in stress resilience and disruptions in endocannabinoid signaling are consistently observed in animal models of depression.

CBD vs THC for Depression: Different Pathways, Different Risks

CBD and THC pose very different levels of risk when administered for treating depression. Whereas CBD is known to be safe and has minimal risk of dependency, THC poses certain risks such as increased anxiety levels, vulnerability to developing psychosis in vulnerable people, and aggravation of depression when taken in high doses for a prolonged time period.

It should be noted that when choosing cannabis as a means of regulating moods:

CBD considerations:

• Non-intoxicating and does not produce a high
• Has demonstrated anxiolytic effects in multiple human trials at doses ranging from 150 mg to 600 mg
• Does not carry the same psychosis risk as THC
• Does not appear to worsen depression with long-term use in the current literature
• Available in hemp-derived form federally and in cannabis-derived form in legal states

THC considerations:

• Produces euphoria at low to moderate doses that may temporarily relieve depressive symptoms
• At high doses or with chronic use, THC has been associated with increased depressive symptoms and emotional blunting
• Patients with a personal or family history of psychosis should exercise significant caution
• The relationship between THC and depression appears to be dose-dependent, with low doses showing more positive effects and high doses showing more negative ones.
• THC tolerance builds relatively quickly, which may reduce its effectiveness as a long-term mood management tool

According to a 2020 review in the Journal of Affective Disorders by Mammen and colleagues, longitudinal data suggest that daily cannabis use is associated with higher rates of depression and anxiety over time, though the direction of causality remains debated since people with depression are also more likely to self-medicate with cannabis.

What the Clinical Research Currently Shows

The clinical studies involving humans that have been conducted using cannabis to treat depression are still very few in number. This is because conducting cannabis research in America is restricted by federal regulations. Nonetheless, the use of cannabidiol (CBD) through observational, open-label studies, and randomized trials has yielded promising results.

Key findings from current research include:

• According to research conducted in 2018 by Turna et al. and published in the Journal of Affective Disorders, 95% of cannabis users utilize cannabis to treat depression, and flower and concentrates were noted as the most useful forms.
• An observational study in 2021 through a commercial cannabis tracking app called Strainprint revealed that users experienced a 50% drop in their depression symptoms after cannabis use, especially those with high levels of CBD. It should be noted that there was no control group, and all results were based on the user’s self-reporting.
• CBD has been shown not to significantly surpass the effect of placebo on psychosis symptoms in an experiment done in 2019 and published in the journal The Lancet Psychiatry.
• A 2023 review in Frontiers in Psychiatry concluded that while preclinical evidence for cannabinoids in depression is strong, human trials remain too heterogeneous in methodology and dosing to draw firm clinical conclusions.

According to Dr. Zach Walsh, a professor of Psychology from the University of British Columbia whose expertise lies in research on cannabis and its effect on mental well-being, current research indicates that “cannabis seems to work best for those individuals who have depression that is associated with pain, insomnia, or anxiety.”

Endocannabinoid Deficiency Theory and Its Relevance to Depression

The clinical endocannabinoid deficiency (CED) hypothesis, proposed by neurologist Dr. Ethan Russo in a 2004 paper in Neuroendocrinology Letters and expanded in subsequent publications, suggests that a deficiency in endocannabinoid tone may underlie several treatment-resistant conditions, including depression, migraine, fibromyalgia, and irritable bowel syndrome.

According to the CED hypothesis, similar to how a lack of dopamine results in Parkinson’s disease, while serotonin imbalance causes depression, a lack of endocannabinoid tone is hypothesized to increase vulnerability to a combination of related disorders that involve heightened pain sensation, mood swings, and autonomic dysfunction.

In the case of patients suffering from depression due to a deficit of endocannabinoids, the idea would be to correct a biochemical imbalance, instead of simply treating the symptoms, through exogenous cannabinoids such as CBD and low THC doses. While the theory is still theoretical and not proven in large studies, it is gaining traction.

The CED hypothesis was reviewed in an article by Dr. Russo in 2016 that appeared in the journal Cannabis and Cannabinoid Research, which reported that there is growing evidence that supports the hypothesis, especially among patients who are resistant to treatment.

Practical Considerations for Patients Exploring Cannabis for Depression

A patient using cannabis as a method of treating depression is encouraged to view cannabis not as an alternative but as a supplement to treatment, under the guidance of a healthcare professional knowledgeable about the use of cannabinoids. Factors such as dose, mode of administration, composition of cannabis, and brain chemistry play major roles.

Practical guidance for patients includes:

• Using CBD-dominant products first and then using THC-containing products later, considering CBD’s better safety profile in treating mood disorders.
• Beginning at the lowest effective dose and titrating slowly, a practice commonly referred to as microdosing, particularly with any THC-containing product.
• Keeping track of one’s mood, sleeping, and anxiety reaction systematically over several weeks rather than determining the efficacy based on a single session.
• Avoiding high-THC, high-frequency use, which current evidence most consistently links to worsening mood outcomes over time
• Talking about the use of marijuana openly to one’s doctor, especially if one is on an SSRI or any other medication for psychiatric problems as the cannabinoids influence the activity of cytochrome P450 enzymes.

For patients in Northern California managing depression alongside mobility limitations or transportation barriers, weed delivery Davis and similar state-licensed services in the Sacramento region provide access to a range of CBD and low-THC products without requiring an in-person dispensary visit, which can be a meaningful practical barrier for those managing fatigue or low motivation as part of their depressive symptoms.

FAQ

Is cannabis an effective treatment for depression?

At present, there is no FDA-approved cannabis-based medicine for treating depression. Studies conducted on this topic have shown promising results, though they are still inadequate. Psychiatrists advise the use of cannabis as a complement rather than a replacement for current medications if the latter fails to alleviate depression.

What is the difference between CBD and THC for depression?

CBD affects the endocannabinoid system indirectly and doesn’t cause any sort of “high” effect. Its anxiolytic and anti-stress properties have been proven in human experiments. Moreover, the side effect profile of CBD is relatively safe. On the other hand, THC binds to the CB1 receptor, causes euphoria at small doses, and can lead to an increased risk of depression at higher doses.

Can cannabis make depression worse?

Yes, especially for heavy users who consume cannabis with high doses of THC or on a daily basis. There is research evidence indicating that heavy usage of cannabis can be linked to increased chances of suffering from depression in the future. For instance, low-dose CBD-dominated usage may not cause any issues at all.

What does the endocannabinoid system have to do with depression?

The endocannabinoid system regulates mood, stress response, emotional memory, and sleep, all of which are disrupted in depression. Endocannabinoid deficiency, specifically low anandamide activity, has been observed in animal models of depression and is theorized to play a role in treatment-resistant cases in humans. Cannabinoids from cannabis interact with this same system, which is why researchers are investigating their potential as mood-regulating agents.

Should I talk to my doctor before using cannabis for depression?

Yes. Cannabis may react with certain psychiatric drugs, including SSRI antidepressants, owing to common metabolic pathways in the liver. The best source of advice would be from a physician who specializes in cannabinoid medicines.

Conclusion

The connection between cannabis and depression is scientifically complicated and currently being researched. The following are established by science: the endocannabinoid system impacts our moods, cannabinoids affect the endocannabinoid system in a way that could be useful when treating depression symptoms, and there may be a complementary advantage of cannabis for a select group of people that includes those with depression who have other conditions like pain, insomnia, and anxiety. Science has not yet found any evidence for using cannabis alone and exclusively for the treatment of clinical depression. People looking into cannabis usage as one of their coping tools would do well to approach it wisely, starting with cannabis rich in CBD and carefully monitoring the results while consulting with their doctor.